Detalles de la búsqueda
1.
Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT.
Blood
; 2024 Mar 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38657278
2.
Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?
Blood
; 2024 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38728380
3.
Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
Cancer
; 2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38758817
4.
Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study.
Cancer
; 2024 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38581695
5.
Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
Am J Hematol
; 99(3): 360-369, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38165072
6.
Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT.
Am J Hematol
; 99(2): 203-215, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38009469
7.
Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT.
Am J Hematol
; 99(5): 993-996, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38385579
8.
High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.
Proc Natl Acad Sci U S A
; 118(22)2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34050021
9.
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
Cancer
; 129(17): 2645-2654, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37269074
10.
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Cancer
; 129(23): 3735-3745, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37658621
11.
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
Br J Haematol
; 201(6): 1169-1178, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36949658
12.
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling.
Haematologica
; 108(4): 1105-1114, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35770529
13.
Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT.
Cancer
; 128(22): 3959-3968, 2022 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36110063
14.
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019.
Br J Haematol
; 197(1): 82-96, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35166376
15.
CAR as Booster to Launch Allogeneic Transplantation in Refractory Leukemia.
N Engl J Med
; 390(16): 1526-1527, 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38657249
16.
Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age.
Am J Hematol
; 97(8): 1065-1074, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35696192
17.
Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis.
Acta Haematol
; 145(4): 419-429, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35231903
18.
Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Cancer
; 127(2): 209-218, 2021 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33119152
19.
Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
Br J Haematol
; 193(3): 592-601, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33838047
20.
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Br J Haematol
; 195(3): 417-428, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34514596